Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
The Lancet. Infectious Diseases
|
April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial
Katrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
Eclinicalmedicine
|
January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Ebiomedicine
|
November 29, 2025
Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort
Jacqueline H Y Siu, Sofia Coelho, Aime Palomeras, et al.
Eclinicalmedicine
|
January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Katrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Lancet (London, England)
|
July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Journal of Crohn'S & Colitis
|
November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib
Zhigang Liu, James L Alexander, Kai Yee Eng, et al.
Eclinicalmedicine
|
October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Zhigang Liu, James L Alexander, Kaixing Le, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV
|
June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
John Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight
|
February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ane Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
The Lancet. Infectious Diseases
|
April 14, 2024
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial
Katrina M Pollock, Álvaro H Borges, Hannah M Cheeseman, et al.
Eclinicalmedicine
|
January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2
Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
Ebiomedicine
|
November 29, 2025
Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort
Jacqueline H Y Siu, Sofia Coelho, Aime Palomeras, et al.
Eclinicalmedicine
|
January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial
Katrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Lancet (London, England)
|
July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
Journal of Crohn'S & Colitis
|
November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or Tofacitinib
Zhigang Liu, James L Alexander, Kai Yee Eng, et al.
Eclinicalmedicine
|
October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
Zhigang Liu, James L Alexander, Kaixing Le, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 5, 2022
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Sarah Fidler, Julie Fox, Timothy Tipoe, et al.
The Lancet. HIV
|
June 21, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
John Frater, Katie J Ewer, Ane Ogbe, et al.
JCI Insight
|
February 22, 2022
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ane Ogbe, Matthew Pace, Mustapha Bittaye, et al.
Page
of 4